Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points

BackgroundCoating of stents has been shown to minimize the interactions between platelets, stent surface and vascular response following stent implantation. The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS® stent with sirolimus-eluting CYPHER® stent for the prevention of symptom-driven clinical end points in a real world clinical setting.MethodsThis prospective registry with a follow-up period of 24 months was conducted in 90 consecutive patients undergoing coronary artery stenting receiving CYPHER® (n = 48) or JANUS® (n = 42) stents. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction and target vessel revascularisation, and the secondary end point was clinically driven in-stent restenosis.ResultsThe primary combined endpoint occurred in 38% of patients (n = 16) in the JANUS® group compared to 10% (n = 5) in the CYPHER® group. The relative risk increase of the composite end point was therefore 63% higher in patients receiving JANUS® stents compared to the CYPHER® stents (crude HR = 1.63, 95% CI = 1.17–2.28, p = 0.004; adjusted HR = 1.79, CI = 1.26–2.55, p = 0.001). Interestingly, 75% of events in the JANUS® group occurred during the first 6 months after stent implantation. Similarly, the rate of clinically driven in-stent restenosis was higher in patients receiving JANUS® stent (n = 10, 2%) compared to the CYPHER® stent (n = 2, 4%). Concordantly, the relative risk for clinically driven in-stent restenosis was 81% higher in the JANUS® group compared to the CYPHER® group (crude HR = 1.81, 95% CI = 1.08–3.02, p = 0.02; adjusted HR = 2.24, CI = 1.26–3.96, p = 0.006).ConclusionThe use of tacrolimus-eluting carbon coated JANUS® stent was associated with worse clinical outcome compared to the sirolimus-eluting CYPHER® stent in clinical routine use.

[1]  C. Beythien,et al.  In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. , 2000, Thrombosis research.

[2]  D. Antoniucci,et al.  Clinical and angiographic outcome after coronary arterial stenting with the carbostent. , 2000, The American journal of cardiology.

[3]  F. Van de Werf,et al.  Evaluation of the biocompatibility of two new diamond-like stent coatings (Dylyn) in a porcine coronary stent model. , 2000, The Journal of invasive cardiology.

[4]  D. Antoniucci,et al.  Clinical and angiographic outcomes following elective implantation of the carbostent in patients at high risk of restenosis and target vessel failure , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  R. Erbel,et al.  Stent Coating: A New Approach in Interventional Cardiology , 2002, Herz.

[6]  M. Aepfelbacher,et al.  Adhesion, cytoskeletal architecture and activation status of primary human macrophages on a diamond-like carbon coated surface. , 2002, Biomaterials.

[7]  D. Trabattoni,et al.  Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  D. Trabattoni,et al.  Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. , 2003, Journal of interventional cardiology.

[9]  Franz Schwarz,et al.  Comparison of stainless steel stents coated with turbostratic carbon and uncoated stents for percutaneous coronary interventions. , 2003, The Journal of invasive cardiology.

[10]  C. Di Mario,et al.  Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease. , 2004, The American journal of cardiology.

[11]  K. Mak,et al.  Clinical impact of stent construction and design in percutaneous coronary intervention. , 2004, American heart journal.

[12]  I. Penn,et al.  Coronary stents: in these days of climate change should all stents wear coats? , 2005, Heart.

[13]  Marco Valgimigli,et al.  The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. , 2005, Journal of the American College of Cardiology.

[14]  G. Nickenig,et al.  Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model , 2005, Zeitschrift für Kardiologie.

[15]  C. Di Mario,et al.  Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[17]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  Timothy J Gardner,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Circulation.

[19]  M. Böhm,et al.  Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model , 2008, Clinical Research in Cardiology.

[20]  Carbo-stent liberador de tacrolimus Janus ® . Resultados inmediatos y seguimiento clínico a medio plazo , 2007 .

[21]  C. Di Mario,et al.  Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent. , 2007, The American journal of cardiology.

[22]  Ya‐Ling Han,et al.  Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. , 2007, Chinese medical journal.

[23]  S. Rodríguez,et al.  [Janus tacrolimus-eluting carbostent. Immediate and medium-term clinical results]. , 2007, Revista espanola de cardiologia.

[24]  W. Koenig,et al.  Angiographic results of a Tacrolimus-eluting stent in acute coronary syndrome lesions , 2009, Clinical Research in Cardiology.

[25]  Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients , 2008, Journal of cardiovascular medicine.

[26]  C. Nienaber,et al.  Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry , 2008, Clinical Research in Cardiology.

[27]  C. Nienaber,et al.  Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry , 2010, Clinical Research in Cardiology.

[28]  M. Böhm,et al.  Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model , 2009, Clinical Research in Cardiology.

[29]  G. Dangas,et al.  Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.